Want to see TNGX full AI Analyst Report?
Tango Therapeutics (TNGX) Income Statement
Tango Therapeutics Income Statement
Last quarter (Q2 2026), Tango Therapeutics's total revenue was $0.00, a decrease of 100.00% from the same quarter last year. In Q2, Tango Therapeutics's net income was $-55.34M. See Tango Therapeutics’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 62.38M | $ 42.07M | $ 36.53M | $ 24.86M | $ 37.04M | |
| $ 60.10M | $ 42.07M | $ 36.53M | $ 24.86M | $ 37.04M | |
| $ 171.39M | $ 187.66M | $ 150.70M | $ 135.93M | $ 95.23M | |
| Depreciation and Amortization | $ 2.28M | $ 2.50M | $ 2.42M | $ 1.61M | $ 897.00K |
| $ -99.31M | $ -127.59M | $ -99.19M | $ -106.51M | $ -57.05M | |
| $ -111.29M | $ -145.59M | $ -114.17M | $ -111.07M | $ -58.19M | |
| $ 9.70M | $ 15.50M | $ 12.56M | $ 2.95M | $ 247.00K | |
| $ -101.59M | $ -130.09M | $ -101.61M | $ -108.12M | $ -57.94M | |
| $ -101.59M | $ -130.30M | $ -101.74M | $ -108.18M | $ -58.23M | |
| Per Share Metrics | |||||
| Basic EPS | $ -0.87 | $ -1.19 | $ -1.08 | $ -1.23 | $ -0.94 |
| Diluted EPS | $ -0.87 | $ -1.19 | $ -1.08 | $ -1.23 | $ -0.94 |
| Weighted Average Shares Outstanding | 116.17M | 109.23M | 94.57M | 87.82M | 62.11M |
| Weighted Average Shares Outstanding (Diluted) | 116.17M | 109.23M | 94.57M | 87.82M | 62.11M |
Currency in USD